Sunday, April 10, 2022

**CTMS01. Biomarker Advances in Clinical Trials**
Great Hall BC, Convention Center  3:00PM–5:00PM CDT

**Inotuzumab Ozogamicin CT027**

Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial

Zhao Y

[View Presentation]

Monday, April 11, 2022

**CTMS02. Patient Selection Strategies for Molecularly Targeted Agents in Clinical Trials**
Great Hall BC, Convention Center  2:30PM–4:30PM CDT

**Talazoparib CT031**

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity

De Bono J

[View Presentation]

Tuesday, April 12, 2022

**PO.CL11.03. Cell-Free DNA 2**
Exhibit Halls D-H, Poster Section 31  1:30PM–5:00PM CDT

**Encorafenib/Binimetinib 3402 / 8**

Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Dummer R

[View Presentation]

**PO.CT03.01. Phase III Clinical Trials**
Exhibit Halls D-H, Poster Section 35  1:30PM–5:00PM CDT

**Lorlatinib CT223 / 2**

Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Bauer T

[View Presentation]